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Background: MicroRNAs have been shown to be important regulators of the immune response and the development
of the immune system. It was reported that microRNA-125b (miR-125b) was down-regulated in macrophages
challenged with endotoxin. However, little is known about the function and mechanism of action of miR-125b in
macrophage activation. Macrophages use L-arginine to synthesize nitric oxide (NO) through inducible NO synthase
(iNOS), and the released NO contributes to the tumoricidal activity of macrophages.
Methods: Luciferase reporter assays were employed to validate regulation of a putative target of miR-125b. The effect
of miR-125b on endogenous levels of this target were subsequently confirmed via Western blot. Quantitative
reverse transcription-polymerase chain reaction (qRT-PCR) was performed to determine the expression level of
miR-125b in macrophage. MTS assays were conducted to explore the impact of miR-125b overexpression on
the cell viability of 4T1 cells.
Results: Here, we demonstrate that mmu-miR-125b overexpression suppresses NO production in activated
macrophages and that LPS-activated macrophages with overexpressed mmu-miR-125b promote 4T1 tumor
cell proliferation in vitro and 4T1 tumor growth in vivo. CCNA2 and eEF2K are the direct and functional
targets of mmu-miR-125b in macrophages; CCNA2 and eEF2K expression was knocked down, which mimicked
the mmu-miR-125b overexpression phenotype.
Conclusions: These data suggest that mmu-miR-125b decreases NO production in activated macrophages at
least partially by suppressing eEF2K and CCNA2 expression.
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Macrophages are key components of the mammalian in-
nate immune system, in which they function in cytokine
release, pathogen killing and antigen presentation to the
adaptive immune system. When cell surface sensing pro-
teins, such as Toll-like receptors (TLRs), recognize and
engage pathogens, macrophages are rapidly activated;
these activated macrophages transform from a relative
quiescent state to an effector state to perform defense
functions [1–5]. Classically activated macrophages, or
M1 macrophages, activate the Th1 immune response* Correspondence: shijuantt@163.com; zhengdx@pumc.edu.cn
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tors, such as cytotoxic TNFα and nitric oxide (NO), to
kill invading pathogens or tumor cells. In fact, the high
expression of inducible NO synthase (iNOS), which
produces NO, is the hallmark of these macrophages.
NO, a free radical gaseous molecule, is a mediator of
vital physiological functions, including host defense.
Many cell types can produce NO using L-arginine via
iNOS. Macrophages are one of the best-characterized
sources of NO. Throughout the last decade, NO has
been identified to play an important role as a first line of
defense against various pathogens. Macrophage uses L-
arginine to synthesize NO via iNOS, and the released NO
contributes to the tumoricidal activity of macrophages. In
early stages of tumor development, macrophages employistributed under the terms of the Creative Commons Attribution 4.0
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high NO concentrations, to induce tumor cell apoptosis
and destroy emerging transformed cells [6–8].
It has been shown that microRNAs (miRs) are
important mediators of macrophage activation. It was
reported that miR-155, miR-146, miR-147, miR-9,
miR-107 and miR-21 are induced by the TLR signal-
ing pathway [9–13]. These miRs can inhibit the
expression of signaling proteins in the inflammatory
signaling cascade and therefore modulate immunity
through feedback mechanisms [10, 12]. MiR-125b, a
homolog of C. elegans miR-lin-4, is deregulated in
most cancers and can regulate cancer cell proliferation via
its target genes [14–19]. It has also been demonstrated
that miR-125b is down-regulated in macrophages in
response to TLR4 signaling [20–24] and enriched in
hematopoietic stem cells, which then enhances
hematopoietic engraftment [25, 26]. The mechanisms by
which macrophages respond to miR-125b and the func-
tion of miR-125b in regulating macrophages remain
unclear.
In the present study, we demonstrate that mmu-
miR-125b (MIMAT0000136) is down-regulated in macro-
phages activated by LPS. Mmu-miR-125b over-expression
inhibits NO production and thus promotes cancer cell
growth both in vitro and in vivo. We further determined
that eEF2K and CCNA2 are the important target genes of
mmu-miR-125b in macrophages. Knockdown of eEF2K
and CCNA2 expression mimics the phenotype of mmu-
miR-125b overexpression in macrophages. These data
suggest that mmu-miR-125b decreases NO production in
activated macrophages to promote cancer cell growth, at
least partially by suppressing eEF2K and CCNA2
expression.
Methods
Isolation of peritoneal macrophage and cell cultivation
Mice were injected intraperitoneally (i. p.) with 2 mL of
3 % thioglycollate (Difco, Detroit, MI, USA). Three days
later, mice were sacrificed by CO2 inhalation followed by
cervical dislocation. Peritoneal exudate cells were
enriched for the peritoneal macrophages using the
method as described by Kumagai et al [27]. Briefly, the
peritoneal cells were harvested by lavage and washed for
three times with the complete culture medium. Approxi-
mately, 1 × 106 cells per well were then cultured for two
hours in six-well plates allowing the macrophages to
adherent. The cells were washed three times with warm
Hank’s balanced salt solution to remove nonadhesive
cells. The adherent macrophages were stimulated with
various concentrations of stimuli and cultured at 37 °C
with 5 % CO2 in DMEM or PRMI-1640 supplemented
with 10 % FBS, 100 U/ml penicillin, and 100 U/ml
streptomycin.Cell lines of human HEK293T, mouse macrophage
RAW264.7 and breast cancer 4T1 originated from the
American Type Culture Collection (Rockville, MD).
These cells were cultured at 37 °C with 5 % CO2 in
DMEM or PRMI-1640 supplemented with 10 % FBS, 100
U/ml penicillin, and 100 U/ml streptomycin. RAW264.7
cells stably transduced with lentivirals pLL3.7-miR-125b
(named as RAW264.7-miR-125b) or control empty vector
pLL3.7 (named as RAW264.7-pLL3.7) were sorted by
FACS. Mmu-miR-125b over-expression was verified by
real-time quantitative PCR (qPCR) carried out in a step-
one Real-time PCR machine (Applied Biosystems, USA).
Quantitative real-time PCR
RNA was isolated with TRIzol (Invitrogen, USA) reagent
according to the manufacturer’s instructions. qPCR was
conducted using a step-one Real-time PCR machine
(Applied Biosystems, USA). SYBR Green PCR Master
Mix (Takara, Shiga, Japan) was used to analyze mmu-
miR-125b, CCNA2 and eEF2K expression. Primer
sequences are listed in Additional file 1: Table S1.
DNA constructs
Mouse pre-miR-125b-2 gene and the 3’ UTR fragment of
CCNA2 and eEF2k containing the putative mmu-miR-
125b target sites and the mutations were amplified by
using the specific PCR primers (The forward and reverse
primers were shown in the Additional file 1: Table S1)
and mouse peripheral blood lymphocyte genomic
DNA as template. The DNA fragments were respectively
cloned into the pLL3.7 vector (Promega, Madison, WI,
USA) downstream of the U6 promoter and the psi-
CHECK2.2 vector (Promega, Madison, WI, USA) down-
stream of the renilla luciferase gene. The DNA constructs
were verified with DNA sequencing by BGI Life Tech Co.
Ltd. (China).
NO detection
NO was determined using a nitrate/nitrite assay kit
(Beyotime Institute of Biotechnology, China). Briefly,
cells were stimulated with LPS for 12 h and the superna-
tants were collected by centrifugation. Concentration of
NO was determined by mixing 50 μl of the supernatants
with 50 μl Griess reagent I and 50 μl Griess reagent II
and measured in a Multiscan ELISA Reader (Assays
HiTech) at 540 nm with appropriate standards (0–60 M)
and normalized by total protein concentration.
Coculture assay
4T1 cells were cocultured with either RAW macro-
phage cells. Briefly, for coculture without cell-cell
contact, 1 × 105 LPS-activated RAW264.7-miR-125b or
RAW264.7-pLL3.7 cells were seeded in Boyden
Transwell inserts (0.4 μm pores; Corning) permeable
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macrophages were then inserted into a 24-well plate
and seeded with 3 × 105 4T1 tumor cells in each well.
The cell viability of 4T1 cells was measured with MTS (3-
(4, 5-dimethylthiazol-2-yl) -5-(3– carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetazolium)) assay according to
the manufacturer’s instruction (Promega, Madison, WI) at
different time points and calculated by the following
formula: Viability (OD) =OD of mix well- OD of control
well.Cell viability assays
Cell viability and growth cure was measured using MTS
assay according to the manufacturer’s instruction. Briefly,
the cells were seeded on 96-well plates at a density of
2 000 cells/well, incubation for indicated time, MTS
solution was added (20μL/well) into the cells, and in-
cubated for 2 h at 37 °C, followed by measuring the
absorbance at 492 nm with a microplate reader.Animal experiments
Animal experiments were performed in accordance with
the institutional guidelines for animal care and were
approved by the committee for the use and care of ani-
mals of the Chinese Academy of Medical Sciences and
Peking Union Medical College, Beijing, China. Briefly,
4T1 (2 × 106) cells and LPS-activated RAW264.7-miR-
125b or RAW264.7-pLL3.7 (5 × 105) cells were subcuta-
neously co-injected into the right flanks of 4 to 6-week-
old BALB/c female mice. Mice were closely monitored
for nearly 1 month. The tumor sizes were measured
every 3 days with a caliper. The tumor volume (V) was
calculated using the formula: V = 0.5 × length × width2.
At the experimental end point, animals were euthanized
and tumors were removed and weighed.Sequence alignment
The mmu-miR-125b seed region and CCNA2, eEF2K
3’ UTR sequences from mouse (Mus musculus) were
obtained and aligned using micoRNA database (http://
www.microrna.org/microrna/getGeneForm.do) or Targets-
can (http://www.targetscan.org/mmu_61/) [28, 29].Luciferase reporter assay
293T cells were co-transfected with pLL3.7-125b or
pLL3.7 and psiCHECK2.2 vector containing 3’ UTRs of
CCNA2, eEF2K or their mutations or miR-125b positive
control. The luciferase activity was quantified after 48 h
transfection using a Dual Luciferase Assay kit (Promega,
Madison, WI). Firefly luciferase activity was normal-
ized to Renilla, and the ratio of Firefly/Renilla value
was reported.Western blot
RAW264.7-miR-125b, RAW264.7-pLL3.7 or RAW264.7
cells were lysed and total 40-60 ng proteins in loading
buffer were denatured for 10 min at 95°C, and then the
proteins were subjected to 10 % SDS-PAGE. The
proteins in the gel were electronically transferred to an
Immobilon-P membrane (Millipore, Eschborn, Germany).
After blocking with 5 % no-fat milk, the membrane was
incubated with a rabbit polyclonal anti-CCNA2 or anti-
eEF2K or anti-GAPDH Ab (1:1000; Cell Signaling Tech-
nology, Beverly, MA) overnight in TBS. The interesting
proteins were visualized using a peroxidase-conjugated
anti-rabbit IgG Ab (1:10000, Cell Signaling Technology,
Beverly, MA) for 1 h and detected by using ECL system
(Amersham Pharmacia Biotech Europe, Freiburg, Germany)
followed by exposure to an X-ray film.
RNA interference
SiRNA used in the experiment was listed in Additional
file 2: Table S2. siRNA duplexes were transfected into
cells using Lipofectamine 2000 (Invitrogen) at a final
concentration of 40 nM.
Statistical analysis
All experiments were at least repeated three times. The
results are presented as mean ± SD. The data were sub-
jected to the Student’s t-test. P < 0.05 was considered
significant.
Results
Mmu-miR-125b expression is down-regulated in activated
macrophages
MiR-125b is an important microRNA in cancer and the
immune response. It has been reported that miR-125b is
down-regulated in macrophages in response to TLR4
signaling [22]. However, little is known about the func-
tion and mechanism of action of miR-125b in macro-
phage activation. To determine the expression level of
mmu-miR-125b in macrophages, mouse RAW264.7 and
peritoneal macrophages were stimulated with LPS at
various concentrations for different time points, and
total RNA was then extracted with TRIzol. Mmu-miR-
125b expression was determined by reverse transcription
using a stem-loop primer (Additional file 1: Table S1)
followed by SYBR Green quantitative PCR (qPCR). As
shown in Fig. 1a, mmu-miR-125b expression decreased
over time in RAW264.7 cells activated with 1 μg/ml
LPS. Mmu-miR-125b expression was also down-
regulated by different concentrations of LPS (Fig. 1b).
Similar results were obtained in peritoneal macrophages
(PMs) activated with LPS (Fig. 1c-d), indicating that
mmu-miR-125b expression is down-regulated in macro-
phages activated by LPS.
Fig. 1 Down-regulation of mmu-miR-125b expression in LPS-activated RAW264.7 cells and peritoneal macrophages. a RAW264.7 cells were
stimulated with 1 μg/ml LPS for the indicated time points. b RAW264.7 cells were stimulated with different concentrations of LPS for 6 h.
c Peritoneal macrophages cells were stimulated with 100 ng/ml LPS for the indicated time points. d Peritoneal macrophages were
stimulated with different concentrations of LPS for 6 h. The expression of mmu-miR-125b was determined by qPCR and normalized to
the expression of U6. The data are presented as the mean ± SD (n = 3) of three independent experiments. **p < 0.01; *p < 0.05
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iNOS expression in activated macrophages
Classically activated, or M1, macrophages are acti-
vated by TLR ligands. In fact, the high expression of
iNOS, which produces NO, is the hallmark of these
macrophages. NO has been shown to play an import-
ant role as a first line of defense against various
pathogens. To assess the role of mmu-miR-125b in
activated macrophages, NO production was evaluated
in macrophages transduced with mmu-miR-125b.
Recombinant lentivirus encoding mmu-miR-125b was
packaged, and RAW264.7 cells were infected with the
lentivirus. Cells with stable expression of mmu-miR-
125b (RAW264.7-miR-125b cells) were sorted by
fluorescence-activated cell sorting (FACS). As shown
in Fig. 2a, mmu-miR-125b expression in RAW264.7-
miR-125b cells was approximately 4-fold higher
compared to that in control cells. Then, RAW264.7-
miR-125b cells were activated with LPS, and the
concentration of NO in the cell lysate was deter-
mined. As shown in Fig. 2b, NO production in LPS-
activated RAW264.7-miR-125b cells was significantly
down-regulated compared to that in control cells
infected with Lenti-GFP control. Real-time qPCR
demonstrated that iNOS mRNA expression was sim-
ultaneously decreased (Fig. 2c). These results on NO
production and iNOS expression were confirmed inperitoneal macrophages transfected with chemically
synthesized miR-125b mimics (Fig. 2d, e). These data
indicate that miR-125b overexpression significantly
suppresses iNOS-catalyzed NO production in LPS-
activated macrophages.
LPS-activated macrophages with miR-125b overexpression
promote tumor cell proliferation
One major function of macrophages is to eliminate
aberrant cells, such as tumorigenic cells. NO is one
of the important molecules that kill tumor cells. To
assess the impact of miR-125b overexpression on the
proliferation of activated macrophages, we performed
a series of ex vivo experiments involving coculture of
4T1 cells with the RAW 264.7 macrophage cell line
without cell-cell contact. To test the effect of miR-
125b on the growth of the macrophage, MTT assay
was conducted to compare the growth rates of the
control and over-expressing macrophages. As shown
in Additional file 3: Figure S1, there was no obvious
difference of growth rate between these two types of
macrophages. However, LPS-activated RAW264.7-
miR-125b cells, but not control cells (RAW264.7-
pLL3.7), significantly promoted the proliferation of
cocultured 4T1 cells without cell-cell contact (Fig. 3a),
suggesting that macrophages with miR-125b overex-
pression enhance tumor cell growth.
Fig. 2 Mmu-miR-125b inhibits NO production and iNOS mRNA expression in LPS-activated RAW264.7 cells and peritoneal macrophages. a The
relative expression of mmu-miR-125b was determined in RAW264.7 cells infected with the pLL3.7-mmu-miR-125b lentivirus and sorted by FACS
for GFP expression. b RAW264.7 cells overexpressing mmu-miR-125b (RAW264.7-miR-125b) and control cells (RAW264.7-pLL3.7, pLL3.7) were
stimulated with 1 μg/ml LPS for 6 h. The supernatants were collected to measure NO using a nitrate/nitrite assay kit and normalized to the
expression of total proteins. c iNOS mRNA levels were measured by qPCR and normalized to the expression of β-actin. d Peritoneal macrophages
were transfected with mmu-miR-125b mimics or controls at a final concentration of 40 nM for 24 h. The cells were stimulated with 100 ng/ml
LPS for 6 h, iNOS mRNA levels were measured by qPCR and normalized to the expression of β-actin. The data are presented as the mean ± SD
(n = 3) of three independent experiments. e The supernatants were collected to measure NO using a nitrate/nitrite assay kit and normalized to
the expression of total proteins. **p < 0.01; *p < 0.5
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To further test whether mmu-miR-125b over-expression
in RAW264.7 cells affects tumor growth in vivo, LPS-
activated RAW264.7-miR-125b or RAW264.7-pLL3.7
control cells and 4T1 cells were mixed at a ratio of
1:4 and then s.c. injected into 4- to 6-week-old
BALB/c female mice. Tumor growth was observed for
21 days, and the tumor length and width were
measured with a caliper every 3 days. At the end of
the experiment, the animals were euthanized, and the
tumors were excised and weighed. As shown in Fig. 3,
both the volume (Fig. 3b-c) and weight (Fig. 3d) of
the tumors derived from LPS-activated RAW264.7-
miR-125b cells plus 4T1 cells were much greater than
those derived from control RAW264.7 cells plus 4T1
cells These results were consistent with the in vitrodata; thus, mmu-miR-125b over-expression in macro-
phages promotes tumor growth in vivo.
Mmu-miR-125b inhibits NO production by targeting
CCNA2 and eEF2K in macrophages
Usually, miRNAs function by targeting protein-coding
genes. Therefore, the direct targets of mmu-miR-125b
were investigated. iTRAQ mass spectrometry-based
protein detection was performed in RAW264.7 cells
transfected with either the mmu-miR-125b over-
expression construct or the control. There were 201
differentially expressed proteins (Additional file 4:
Table S3) that were decreased more than 25 %
compared with the control, suggesting that these 201
genes were probably regulated by mmu-miR-125b. These
201 genes were analyzed using TargetScan (http://
www.targetscan.org/mmu_61/) and the microRNA
Fig. 3 LPS-activated RAW264.7-miR-125b cells promote 4T1 cell proliferation in vitro and in vivo. a 4T1 cells were cocultured with either RAW
macrophage cells. Briefly, for coculture without cell-cell contact, 1 × 105 LPS-activated RAW264.7-miR-125b or RAW264.7-pLL3.7 cells were seeded
in Boyden Transwell inserts. Transwells containing macrophages were then inserted into a 24-well plate and seeded with 3 × 105 4T1 tumor cells
in each well. The cell viability of 4T1 cells was measured with MTS assay at different time points. Each bar represents the mean ± SD (n = 3) of
three independent experiments. **p < 0.01; *p < 0.05. b-d. LPS-activated RAW264.7-miR-125b cells promote tumor growth in vivo. 4T1 cells and
LPS-activated RAW264.7-miR-125b cells or LPS-activated RAW264.7-pLL3.7 cells were mixed at a ratio of 4:1 and then s.c. co-injected into 4- to
6-week-old BALB/c female mice. After 5 days, tumor length and width were measured with a caliper every 3 days for 3 weeks. The tumor volume
at different time points is shown in panels b and c. Individual tumor weights and the average tumor weight at the experimental endpoint are
shown in panels d. **p < 0.01; *p < 0.05
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confirm the direct targets of mmu-miR-125b. Bioinfor-
matics analysis of potential mmu-miR-125b binding sites
revealed that the 3’ UTR of CCNA2 and eEF2K each har-
bor a conserved mmu-miR-125b binding site (Fig. 4a-b).
To confirm the regulatory interaction, the effects of mmu-
miR-125b on eEF2K and CCNA2 reporter genes were
evaluated. Luciferase reporter assays confirmed that
CCNA2 and eEF2K expression was indeed repressed by
mmu-miR-125b via the 3’ UTR (Fig. 4c-d). CCNA2 and
eEF2K protein levels were shown to be down-regulated in
LPS-activated RAW264.7-miR-125b cells by western blot
(Fig. 4e). Mmu-miR-125b is down-regulated in LPS-
activated macrophages, and, accordingly, the targets of
mmu-miR-125b are expected to be upregulated in LPS-
activated macrophages. Through western blotting, we
found that eEF2K and CCNA2 were upregulated in LPS-
activated macrophages (Fig. 4f). These data indicate that
the mmu-miR-125b-mediated inhibition of NO produc-
tion might occur via targeting eEF2K and CCNA2 in
macrophages.
The association of eEF2K and CCNA2 with macro-
phage activation has not been previously reported.
Therefore, to confirm the role of eEF2K and CCNA2 in
NO production in macrophages, eEF2K and CCNA2
were knocked down in LPS-activated RAW264.7 cellsusing RNA interference technology (siRNA sequences
are provided in Additional file 2: Table S2), and then
NO production and iNOS expression were examined. As
shown in Fig. 5, knockdown of eEF2K and CCNA2
(Fig. 5a-b) resulted in a significant decrease in NO
production (Fig. 5c) and iNOS gene expression (Fig. 5d).
Thus, eEF2K and CCNA2 knockdown in RAW264.7
cells mimics the mmu-miR-125b over-expression
phenotype. Taken together, our data suggest that eEF2K
and CCNA2 are the primary targets of mmu-miR-125b
in the regulation of NO production in activated
macrophages.
Discussion
In the present study, we demonstrate that mmu-miR-125b
is down-regulated in LPS-activated RAW264.7 cells and
peritoneal macrophages and that over-expression of
mmu-miR-125b inhibits iNOS expression and NO
production in these cells. There have been reports that
miR-125b expression decreases in macrophages 3 h after
inflammatory stimulation [21, 23]; thus, miR-125b down-
regulation may serve as a natural mechanism to promote
the inflammatory response.
iNOS induction and NO production are important
macrophage functions related to killing NO-sensitive
tumors; indeed, tumor cell killing is one of the major
Fig. 4 Validation of mmu-miR-125b targets. a-b Alignment of potential mmu-miR-125b binding sites and mutations in the 3’ UTR of CCNA2 and
eEF2K mRNA in mus musculus. c-d The intact or mutant 3’ UTR of the indicated genes were cloned into the psiCHECK2.2 luciferase reporter vector
and then co-transfected with a mmu-miR-125b expression vector (miR-125b) or pLL3.7 (control) into 293T cells. Luciferase activity was analyzed 48 h
after transfection using a dual luciferase reporter assay. 125b positive means the psiCHECK2.2 luciferase reporter vector include a sequence totally
combined to miR-125b seed sequence. The results are expressed as the relative luciferase activity (firefly/renilla luciferase). The data are presented as
the mean ± SD (n = 3) of three independent experiments. e The protein levels of CCNA2 and eEF2K in 24 h after 1 μg/ml LPS-activated RAW264.7-miR-
125b and control cells were determined by western blot; GAPDH served as the loading control. f The protein levels of CCNA2 and eEF2K in 1 μg/ml
LPS-activated RAW264.7 cells at different time points were determined by western blot; GAPDH served as the loading control. **p < 0.01; *p < 0.05
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Therefore, the cytotoxic effects of NO on NO-sensitive
cancer cells comprise part of the immune response
against tumors [31, 32]. It is well known that TAMs
(tumor-associate macrophages) have a reduced capacity
to produce anti-tumor molecules, such as NO, TNFα,
ROS, and IL-1; instead, TAMs support tumor survival,
growth and metastasis and play a pivotal role in tumor
angiogenesis and immune evasion [8, 33, 34]. We alsofound that mmu-miR-125b levels are up-regulated in
mouse breast cancer TAMs (data not show). Thus, regu-
lating miR-125b expression might be a potential strategy
for influencing macrophage function and eliminating
certain cancers.
CCNA2 (NM_009828.2) is critical for the initiation of
DNA replication, transcription and cell cycle regulation.
CCNA2 has been reported to be a key regulator of cell
differentiation, and it can switch the differentiation
Fig. 5 Knockdown of CCNA2 and eEF2K inhibits NO production and iNOS expression in LPS-activated RAW264.7 cells. a RAW264.7 cells were
transfected with CCNA2 and eEF2K siRNA at a final concentration of 40 nM for 48 h; mRNA levels were determined by qPCR and normalized to
β-actin. b After 60 h, protein expression was determined by western blot; GAPDH served as the loading control. c RAW264.7 cells were transfected
with CCNA2 and eEF2K siRNA at a final concentration of 40 nM; after 60 h, the cells were stimulated with 1 μg/ml LPS for 6 h. NO in the supernatant
was measured using a nitrate/nitrite assay kit, and the values were normalized to total protein concentration. d iNOS mRNA expression was detected
by qPCR and normalized to β-actin. The data are presented as the mean ± SD (n = 3) of three independent experiments. **p < 0.01; *p < 0.05
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[35, 36]. eEF2K (NM_007908.4) is a Ca2+/calmodulin-
dependent protein kinase that regulates JNK (c-jun N-
terminal kinase) and NF-κB (nuclear factor-kappa B) p65
phosphorylation as well as reactive oxygen species
(ROS) production and also affects the development of
hypertension [37, 38]. We demonstrated that the
knockdown of eEF2K and CCNA2 significantly de-
creases NO production and iNOS gene expression in
activated macrophages. The association of eEF2K and
CCNA2 with macrophage activation has not been
previously reported. However, the other functions and
mechanisms of action of eEF2K and CCNA2 in acti-
vated macrophages need to be further clarified.
The level of iNOS expression and NO production
suppression suggests that mmu-miR-125b is a con-
tributing albeit relatively modest impact on the regu-
lation of the NO production pathway. The biological
process is complex and is regulated by signal pathway
network. There might be multiple factors to regulate
the NO production pathway and mmu-miR-125b
might be one of molecules in this complex network.
Similarly, it seems that the modest effect of si-RNA
knockdown of eEF2K and CCNA2 transcripts on NO
production and iNOS expression also argues that thecontributions of mmu-miR-125b and its target genes.
Numerous studies revealed a one-to-one relationship
between miRNA and its target gene. However, one
miRNA may regulate many genes as its targets, while
one gene may be targeted by many miRNAs. So the
effect of miRNA regulation on mRNA and protein
levels is usually quite modest and associated pheno-
types are often weak or subtle. It is now becoming
clear that complex regulatory networks between miR-
NAs and their gene targets are actually common
mechanisms that have evolved in gene regulation.
Therefore, our data suggest that mmu-miR-125b
decreases NO production in activated macrophages
partially by suppressing eEF2K and CCNA2 expres-
sion because of the complex regulatory networks.
LPS was used to activate macrophages in this study
because it was a stimulator of M1 macrophages which
could secrete high amounts of pro-inflammatory
mediators to kill invading pathogens or tumor cells. It
is not typical experimental designs to directly test
mechanistic hypothesis. But the results obtained from
LPS activated macrophages suggested the possibility
of reverse tumor-polarized tumor associated macro-
phages phenotype and re-educate them to kill tumor
cells by M1 stimulators.
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We have shown in this study that increased mmu-miR-
125b expression in macrophages promotes 4T1 cell
growth in vitro and in vivo. Therefore, knockdown of
miR-125b expression in macrophages in the tumor
microenvironment may be a useful strategy for the treat-
ment of certain cancers. These findings may extend our
understanding of the function of miR-125b in regulating
macrophage activation and the immune response.
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